SSpliceBio
SpliceBio is a clinical-stage genetic medicines company based in Barcelona that uses a proprietary Protein Splicing platform built on engineered inteins from Tom Muir's lab at Princeton University, allowing large genes to be split across dual AAV vectors and reassembled inside cells — overcoming the size limit that blocks conventional gene therapy. Its lead program, SB-007, targets Stargardt disease and is in the Phase 1/2 ASTRA clinical study, alongside a pipeline in ophthalmology, CNS and other genetic diseases, plus a collaboration with Spark Therapeutics worth up to ~$216M. In June 2025 it closed a $135M (€118M) Series B led by EQT Life Sciences and Sanofi Ventures — the largest biotech financing round ever raised in Spain — bringing total funding to over $200M.
Founders
Global models 5
K
B
A
4In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 10
Open as list →
Y
E
A
C
G
N
RFunding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-11 | Series B | $135M |
EQT Life Sciences, Sanofi Ventures
+7 more
|
| 2022-02-16 | Series A | €50M |
UCB Ventures, Ysios Capital
+4 more
|
| 2020-09-15 | Seed | — |
Ysios Capital
+2 more
|